OKYO Pharma Stock Rises 8% On Positive Phase 2 Trial Results For Neuropathic Corneal Pain Therapy

(RTTNews) - OKYO Pharma Limited (OKYO) shares climbed 8.00 percent to $2.97 on Wednesday after the company reported positive top-line data from its Phase 2 trial of urcosimod for neuropathic corneal pain, a condition with no FDA-approved treatment. OKYO opened at $3.00 and traded between $2.46 and $3.10 on volume of 1.12 million shares, well above its average of 163,273 on theNasdaq. The stock's 52-week range is $0.81 to $3.11. The randomized, placebo-controlled study showed that patients receiving 0.05 percent urcosimod experienced a mean pain score reduction of 5.5 versus 2.75 for placebo, with 75 percent of patients in the urcosimod group achieving over 80 percent improvement. Statistically significant reductions were observed by Week 4, and the therapy was well-tolerated.